Pituitary-dependent Cushing’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pituitary-dependent Cushing’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of SPI-62 for Treating ACTH-Dependent Cushing’s Syndrome in Patients with Cushing’s Disease or Ectopic ACTH/CRH Secretion https://clinicaltrials.eu/trial/study-of-spi-62-for-treating-acth-dependent-cushings-syndrome-in-patients-with-cushings-disease-or-ectopic-acth-crh-secretion/ Wed, 29 Apr 2026 14:58:48 +0000 https://clinicaltrials.eu/trial/study-of-spi-62-for-treating-acth-dependent-cushings-syndrome-in-patients-with-cushings-disease-or-ectopic-acth-crh-secretion/ This clinical trial is focused on studying a condition known as Cushing’s Syndrome, which is a disorder caused by high levels of the hormone cortisol in the body. The trial will specifically look at a type of Cushing’s Syndrome that depends on a hormone called adrenocorticotropic hormone (ACTH). This includes conditions like Cushing’s Disease, where the pituitary gland produces too much ACTH, and other forms where ACTH is produced outside the pituitary gland. The treatment being tested is a medication called SPI-62, which is a new type of drug designed to reduce the effects of cortisol by inhibiting an enzyme called 11β-hydroxysteroid dehydrogenase type 1 (HSD-1).

The purpose of the study is to understand how SPI-62 affects people with ACTH-dependent Cushing’s Syndrome. Participants in the study will take the medication in the form of a film-coated tablet, which is taken orally. The study will last for several weeks, during which participants will be monitored for changes in their condition. This includes measuring the levels of certain substances in their urine and blood to see how the medication is working. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they might experience. The study will also look at how the medication affects other health issues related to Cushing’s Syndrome, such as blood sugar levels, cholesterol, blood pressure, and bone health. The trial aims to provide valuable information on the safety and effectiveness of SPI-62 as a treatment option for people with this condition.

]]> Study of Osilodrostat for Children and Adolescents with Cushing’s Disease https://clinicaltrials.eu/trial/study-of-osilodrostat-for-children-and-adolescents-with-cushings-disease/ Wed, 29 Apr 2026 14:58:27 +0000 https://clinicaltrials.eu/trial/study-of-osilodrostat-for-children-and-adolescents-with-cushings-disease/ This clinical trial is focused on studying Cushing’s disease, a condition where the body produces too much of a hormone called cortisol. The study involves a medication called osilodrostat, also known by its code name LCI699. Osilodrostat is available in the form of film-coated tablets, with doses of 1 mg, 5 mg, and 10 mg. The purpose of the study is to understand how osilodrostat is processed in the body and how well it is tolerated by children and adolescents aged 6 to under 18 years who have Cushing’s disease.

Participants in the study will take osilodrostat orally, meaning they will swallow the tablets. The study will last for a period of up to 48 weeks. During this time, researchers will monitor how the medication affects the levels of cortisol in the body and assess any side effects. The study aims to gather information on the safety and effectiveness of osilodrostat in managing Cushing’s disease in young patients.

Throughout the study, participants will have regular check-ups to track their progress and ensure their well-being. The study will help determine if osilodrostat can be a suitable treatment option for children and adolescents with Cushing’s disease, especially for those who have not had success with surgery or are waiting for surgery. The findings from this study could provide valuable insights into managing this condition in younger patients.

]]> Study of Lu AG13909 in Adults with Cushing’s Disease to Evaluate Safety and Effectiveness https://clinicaltrials.eu/trial/study-on-the-effects-of-ag13909-for-adults-with-cushings-disease/ Wed, 29 Apr 2026 14:27:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ag13909-for-adults-with-cushings-disease/ The clinical trial investigates a new treatment for Cushing’s disease, a rare condition where the body produces too much of a hormone called cortisol. The excess cortisol is caused by high levels of another hormone called adrenocorticotropic hormone (ACTH) that comes from the pituitary gland in the brain. This condition can lead to various health problems if left untreated.

The study will test a new medicine called Lu AG13909, which is a humanized antibody that targets ACTH. The medication will be given in two different ways: as an injection under the skin (subcutaneous use) and through a vein (intravenous use). The study aims to understand how well the medicine works in controlling cortisol levels and how safe it is for patients.

During the trial, participants will receive the study medication for up to 910 days. The researchers will monitor the amount of cortisol in participants’ urine and how the medicine moves through the body. They will also track any side effects that may occur during the treatment period. This is a Phase II trial, which means the medication has already been tested for basic safety in humans, and now researchers are studying how well it works for treating Cushing’s disease.

]]>